文献速递神经肿瘤脊柱脊髓外科

肾细胞癌脊柱转移:单中心手术结局与并发症分析

Metastatic Renal Cell Carcinoma to the Spine: Outcomes and Morbidity: Single-Center Experience.
PubMed 文献 · World Neurosurg · 2021-07-17

该单中心回顾性研究纳入2007至2020年接受手术的44例肾细胞癌脊柱转移患者,中位术后生存8个月,随访ASIA E评分与较高Tokuhashi评分与总生存改善相关,并发症率为16%。

要点

  • 肾细胞癌脊柱转移术后中位生存仅8个月,手术指征为保留功能与预防神经恶化。
  • 随访ASIA E评分(HR 0.109,95%CI 0.022-0.534,P=0.006)与生存改善独立相关。
  • Tokuhashi评分12-15分者中位生存23.4个月,显著优于低分组的6.5与8.9个月(P=0.03)。

核心结论

  • 肾细胞癌脊柱转移患者术后中位生存为8(0.3-92)个月,较高Tokuhashi评分与随访ASIA E评分与总生存改善相关,并发症率为16%。

研究设计与样本

  • 单中心回顾性研究,纳入2007至2020年接受手术治疗的44例肾细胞癌脊柱转移患者。

主要发现

  • 疼痛为最常见症状,约三分之一病例存在神经功能障碍。
  • 胸椎为最常见受累部位(N=27),其次为腰椎(N=12)和颈椎(N=5)。
  • 肾细胞癌诊断后总生存为25(2-194)个月,脊柱手术后为8(0.3-92)个月。
  • Tokuhashi评分0-8、9-11、12-15组的中位生存分别为6.5(1.5-23.5)、8.9(0.3-91.6)、23.4(2.5-66)个月(P=0.03)。
  • 随访ASIA E评分与生存改善显著相关(HR 0.109,95%CI 0.022-0.534,P=0.006)。

关键数值与推荐

  • 性别、年龄、脊柱节段、术后放疗及肾切除术对生存无显著影响。

临床怎么用

  • 对肾细胞癌脊柱转移患者,手术适用于保留功能和预防神经功能恶化。
  • Tokuhashi评分和随访ASIA评分可用于评估生存预后。

局限性

  • 单中心回顾性研究,样本量44例,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Renal cell carcinoma with metastases to the spine (RCCMS) requires a multidisciplinary approach. We reviewed our institutional experience with RCCMS patients undergoing spinal surgery in order to identify factors that may affect clinical outcomes, survival, and complications. METHODS: Patients with RCCMS who underwent operative intervention from 2007 to 2020 were reviewed retrospectively. RESULTS: Forty-four patients with the diagnosis of RCCMS were identified. Pain was the most common symptom, and neurologic dysfunction was present in one third of cases. Thoracic spine was the most common location (N = 27), followed by the lumbar (N = 12) and cervical (N = 5) regions. The overall survival from diagnosis of renal cell carcinoma was 25 (2 - 194) months and 8 (0.3 - 92) months after spinal surgery. Gender, age, spinal level, postoperative radiation, and nephrectomy had no bearing on survival. Survival for patients with a Tokuhashi score of 0 - 8, 9 - 11, and 12 - 15 was 6.5 (1.5 - 23.5), 8.9 (0.3 - 91.6), and 23.4 (2.5 - 66) months, respectively (P = 0.03). The postoperative American Spinal Cord Injury Association score of E (hazard ratio 0.109 [95% confidence interval 0.022 - 0.534, P = 0.006) also bore a significant influence on survival. There was a total of 10 complications in 7 of 44 (16%) patients. CONCLUSIONS: Median postoperative survival of patients with RCCMS was 8 (0.3 - 92) months. Higher Tokuhashi score and ASIA E score at follow-up correlated with improved overall survival. Complication rate was 16%. Spinal surgery in RCCMS is indicated for the preservation of function and prevention of neurologic deterioration. Multimodality therapy with improved chemotherapy and stereotactic spinal radiation is expected to impact quality and length of survival positively.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Park BJ, Seaman SC, Noeller JL, et al. Metastatic Renal Cell Carcinoma to the Spine: Outcomes and Morbidity: Single-Center Experience. World Neurosurg. 2021. PMID: 34280537. doi:10.1016/j.wneu.2021.07.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。